The past decade has witnessed a true revolution in our understanding of how RNA can act as regulator of gene functions. Central to these new advances is a growing appreciation that small interfering RNAs (siRNAs) can induce sequence-specific destruction of homologous mRNAs in mammalian cells via a natural process referred as RNA interference (RNAi). During a period of only five years, RNAi has grown from a biological phenomenon to one of the most widely used tools in research. In effort to facilitate functional genomics with RNAi, several libraries of siRNAs or short hairpin RNAs have been constructed and screened in vitro and in vivo. Although RNAi has many advantages over other methods such as antisense and ribozyme technologies, the specificity of silencing is not absolute and there is a danger of "off-target effects," and activation of the innate immunity. Notably, the success of siRNAs as therapeutic agents largely depends on the development of a delivery vehicle that can efficiently deliver them to specific tissues or cells. A deeper understanding of the mechanisms of RNAi should allow better design of siRNA agents. The purpose of this issue is to review this exciting field and to provide the reader with current design rules, delivery strategies, and methods to minimize unintended siRNA effects.

It should be noted that the emergence of RNAi has helped to clarify another enigma of noncoding temporal RNAs or microRNAs (miRNAs). These tiny RNA regulators are being implicated in diverse biological pathways, ranging from development to neuronal differentiation and insulin production. In addition to their roles in cell biology, recent studies have implicated miRNAs in tumorogenesis and metastasis. Indeed, gene profiling analysis found a number of miRNAs that were upregulated in various cancers, which suggests a potential diagnostic and prognostic value. Also, the identification of virus-encoded miRNAs indicate that some viruses are able of exploiting RNA silencing as a convenient method for gene regulation of host and viral genes. Although we have learned much about the general mechanism underlying miRNA biogenesis, a detailed understanding of how miRNAs and related small RNAs work remains to be elucidated. This issue on RNAi also highlights the recent advances in understanding the biogenesis and expression of miRNAs in mammalian cells.

As our understanding of the functions of small RNAs and the mechanisms by which RNA activate innate immunity continues to increase, we should become better equipped to translate this naturally occurring process into our own therapeutic benefit.
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